Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
161 hedge funds and large institutions have $771M invested in Achillion Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 48 increasing their positions, 34 reducing their positions, and 18 closing their positions.
256% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 18
223% more call options, than puts
Call options by funds: $139M | Put options by funds: $43.2M
41% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 34
40% more funds holding
Funds holding: 115 → 161 (+46)
23% more capital invested
Capital invested by funds: $627M → $771M (+$144M)
7.63% less ownership
Funds ownership: 84.74% → 77.11% (-7.6%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$33.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$25.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.6M |
| 4 |
Goldman Sachs
New York
|
+$8.81M |
| 5 |
Millennium Management
New York
|
+$8.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$147M |
| 2 |
QF
QVT Financial
New York
|
-$45.3M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$23.7M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$7.78M |
| 5 |
Morgan Stanley
New York
|
-$7.18M |
ACHN Hedge Fund Activity: Q3 2014 in Review
161 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2014, worth a combined $771M — up 23% from $627M a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new ACHN positions and 18 closed out — a net gain of 46 holders — while 48 added to existing stakes and 34 trimmed.
The largest buyer was Janus Henderson Investors US, opening a new position worth an estimated $33.5M. The largest seller was RA Capital Management, cutting an estimated $147M.
- 161 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2014, up from 115 in Q2 2014.
- Funds reported $771M of Achillion Pharmaceuticals stock for Q3 2014, up 23% quarter-over-quarter.
- 64 funds opened new Achillion Pharmaceuticals positions in Q3 2014 and 18 closed out, a net change of +46 holders.
- The largest Achillion Pharmaceuticals buyer in Q3 2014 was Janus Henderson Investors US, an estimated $33.5M added.
- The largest Achillion Pharmaceuticals seller in Q3 2014 was RA Capital Management, an estimated $147M sold.
Based on aggregated 13F filings for Q3 2014.